Amalia Mester, Maximilian Gabriel, Ingrid Boldin, Haleh Aminfar, Nora Woltsche, Astrid Heidinger, Andreas Guttmann, Paul Wintersteller, Jutta Horwath-Winter
{"title":"The Performance of Topical Insulin in Persistent Corneal Epithelial Defects and Persistent Corneal Ulcers - A Case Series.","authors":"Amalia Mester, Maximilian Gabriel, Ingrid Boldin, Haleh Aminfar, Nora Woltsche, Astrid Heidinger, Andreas Guttmann, Paul Wintersteller, Jutta Horwath-Winter","doi":"10.1080/02713683.2025.2456784","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To retrospectively describe the performance of topical insulin in persistent corneal epithelial defects (CED) and persistent corneal ulcers.</p><p><strong>Methods: </strong>We reviewed cases of patients treated for persistent CED and persistent corneal ulcers using topical insulin in a concentration of 25 IU per milliliter three times per day. The closure rate of CED and corneal ulcers was the main outcome measure.</p><p><strong>Results: </strong>Thirty-seven episodes of 29 patients treated with topical insulin were reviewed. There was a wide range of additionally used medication, underlying pathologies as well as ocular and systemic comorbidities in our cohort. On average, insulin drops were started after 36 days of conventional therapy (SD 59, range 0-193) and were used for 42 days (SD 38, range 3-130). Therapy success was achieved in 15 of 28 (53.5%) cases with CED and in 4 of 9 (44%) cases with corneal ulcers. While insulin generally showed a good safety profile, one patient reported intolerable discomfort related to the use of topical insulin.</p><p><strong>Conclusion: </strong>Topical insulin may be considered as a treatment option in complicated cases refractory to conventional treatment, but outcomes may be less favorable than previously reported.</p>","PeriodicalId":10782,"journal":{"name":"Current Eye Research","volume":" ","pages":"1-4"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Eye Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02713683.2025.2456784","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To retrospectively describe the performance of topical insulin in persistent corneal epithelial defects (CED) and persistent corneal ulcers.
Methods: We reviewed cases of patients treated for persistent CED and persistent corneal ulcers using topical insulin in a concentration of 25 IU per milliliter three times per day. The closure rate of CED and corneal ulcers was the main outcome measure.
Results: Thirty-seven episodes of 29 patients treated with topical insulin were reviewed. There was a wide range of additionally used medication, underlying pathologies as well as ocular and systemic comorbidities in our cohort. On average, insulin drops were started after 36 days of conventional therapy (SD 59, range 0-193) and were used for 42 days (SD 38, range 3-130). Therapy success was achieved in 15 of 28 (53.5%) cases with CED and in 4 of 9 (44%) cases with corneal ulcers. While insulin generally showed a good safety profile, one patient reported intolerable discomfort related to the use of topical insulin.
Conclusion: Topical insulin may be considered as a treatment option in complicated cases refractory to conventional treatment, but outcomes may be less favorable than previously reported.
目的:回顾性描述外用胰岛素治疗持续性角膜上皮缺损(CED)和持续性角膜溃疡的疗效。方法:我们回顾了治疗持续性CED和持续性角膜溃疡的患者,使用浓度为25 IU /毫升的局部胰岛素,每天三次。CED和角膜溃疡的闭合率是主要的结局指标。结果:回顾性分析了29例37次局部胰岛素治疗的临床资料。在我们的队列中,有广泛的额外使用的药物,潜在的病理以及眼部和全身合并症。平均而言,胰岛素滴注在常规治疗36天后开始(SD 59,范围0-193),使用42天(SD 38,范围3-130)。28例CED患者中有15例(53.5%)治疗成功,9例角膜溃疡患者中有4例(44%)治疗成功。虽然胰岛素总体上显示出良好的安全性,但一名患者报告了与局部使用胰岛素相关的无法忍受的不适。结论:局部胰岛素可作为常规治疗难治性复杂病例的一种治疗选择,但结果可能不如先前报道的好。
期刊介绍:
The principal aim of Current Eye Research is to provide rapid publication of full papers, short communications and mini-reviews, all high quality. Current Eye Research publishes articles encompassing all the areas of eye research. Subject areas include the following: clinical research, anatomy, physiology, biophysics, biochemistry, pharmacology, developmental biology, microbiology and immunology.